Drugs / CAR19 T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02431988 | Jun 2016 → Feb 2020 | diffuse large B-cell lymphoma | University College, London | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR19 T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02431988 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor T-cells” NCT02431988 ↗ |
| Target | CD19 | “CD19 specific Chimeric Antigen Receptor T-cells” NCT02431988 ↗ |